Aortic sclerosis, aortic stenosis and lipid-lowering therapy

References

• Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J. Am. Coll. Cardiol.21, 1220–1225(1993).
   PubMed Web of Science ®Google Scholar
• Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol.29, 630–634(1997).
   PubMed Web of Science ®Google Scholar
• Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med.341, 142–147 (1999).
   PubMed Web of Science ®Google Scholar
• Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol.48, e1–e148 (2006).
   Google Scholar
• Iung B, Baron G, Butchart EG et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur. Heart J.24, 1231–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Novaro GM, Katz R, Aviles RJ et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J. Am. Coll. Cardiol.50, 1992–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Brener SJ, Duffy CI, Thomas JD, Stewart WJ. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J. Am. Coll. Cardiol.25, 305–310 (1995).
   PubMed Web of Science ®Google Scholar
• Faggiano P, Ghizzoni G, Sorgato A et al. Rate of progression of valvular aortic stenosis in adults. Am. J. Cardiol.70, 229–233 (1992).
   PubMed Web of Science ®Google Scholar
• Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J. Am. Coll. Cardiol.13, 545–550 (1989).
   PubMed Web of Science ®Google Scholar
• Peter M, Hoffmann A, Parker C, Luscher T, Burckhardt D. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest103, 1715–1719 (1993).
   PubMed Web of Science ®Google Scholar
• Roger VL, Tajik AJ, Bailey KR, Oh JK, Taylor CL, Seward JB. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am. Heart J.119, 331–338 (1990).
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Klaar U, Schemper M et al. Mild and moderate aortic stenosis; Natural history and risk stratification by echocardiography. Eur. Heart J.25, 199–205 (2004).
   PubMed Web of Science ®Google Scholar
• Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation103, 1522–1528 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol.16, 523–532 (1996).
   PubMed Web of Science ®Google Scholar
• Chan KL. Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol.42, 593–599 (2003).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium and phosphorus, diabetes mellitus, aortic valve stenosis and history of systemic hypertension with presence or absence of mitral anular calcium in persons older than 62 years in a long-term health care facility. Am. J. Cardiol.59, 381–382 (1987).
   PubMed Web of Science ®Google Scholar
• Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J. Chronic Dis.37, 407–415 (1984).
   PubMedGoogle Scholar
• Isner JM, Sours HE, Paris AL, Ferrans VJ, Roberts WC. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation60, 1401–1412 (1979).
   PubMed Web of Science ®Google Scholar
• Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors – a causal relationship? A clinical morphologic study. Clin. Cardiol.14, 995–999 (1991).
   PubMed Web of Science ®Google Scholar
• Sprecher DL, Schaefer EJ, Kent KM et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am. J. Cardiol.54, 20–30 (1984).
   PubMed Web of Science ®Google Scholar
• Messika-Zeitoun D, Bielak LF, Peyser PA et al. Aortic valve calcification: determinants and progression in the population. Arterioscler. Thromb. Vasc. Biol.27, 642–648 (2007).
   PubMed Web of Science ®Google Scholar
• Pohle K, Maffert R, Ropers D et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation104, 1927–1932 (2001).
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Subramaniam M, Springett M et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation105, 2660–2665 (2002).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am. J. Cardiol.88, 693–695 (2001).
   PubMed Web of Science ®Google Scholar
• Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol.40, 1723–1730 (2002).
   PubMed Web of Science ®Google Scholar
• Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation104, 2205–2209 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation110, 1291–1295 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Binder T, Porenta G et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N. Engl. J. Med.343, 611–617 (2000).
   PubMed Web of Science ®Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al. A Randomized Trial of Intensive Lipid Lowering Therapy in Calcific Aortic Stenosis. N. Engl. J. Med.2005.
   PubMedGoogle Scholar
• Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol.49, 554–561 (2007).
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aortic-valve disease. N. Engl. J. Med.349, 717–718 (2003).
   PubMed Web of Science ®Google Scholar
• Chandra HR, Goldstein JA, Choudhary N et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J. Am. Coll. Cardiol.43, 169–175 (2004).
   PubMed Web of Science ®Google Scholar
• Shah SJ, Ristow B, Ali S, Na BY, Schiller NB, Whooley MA. Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am. J. Cardiol.99, 1128–1133 (2007).
   PubMed Web of Science ®Google Scholar
• Hayek T, Attias J, Coleman R et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc. Res.44, 579–587 (1999).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol.26, 1133–1139 (1995).
   PubMed Web of Science ®Google Scholar
• Tummala PE, Chen XL, Sundell CL et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation100, 1223–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Alcalai R, Viola N, Mosseri M et al. The value of percutaneous coronary intervention in aortic valve stenosis with coronary artery disease. Am. J. Med.120, 185 e7–13 (2007).
   Google Scholar
• Chan KL, Teo K, Tam J, Dumesnil JG. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am. Heart J.153, 925–931 (2007).
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol.99, 970–973 (2007).
   PubMed Web of Science ®Google Scholar